Chemistry:Adrogolide

From HandWiki

Adrogolide (INN; developmental code names A-93431, ABT-431, and DAS-431), also known as adrogolide hydrochloride (USAN) in the case of the hydrochloride salt, is a dopamine D1-like receptor agonist which was under development for the treatment of Parkinson's disease, cognition disorders, and cocaine-related disorders but was never marketed.[1][2][3][4][5]

It is a chemically stable and rapidly converted diacetate ester prodrug of the highly selective dopamine D1 and D5 receptor full agonist A-86929.[4] The effects of adrogolide and A-86929 in animals and humans have been studied.[4][5] Side effects of adrogolide in humans included injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, and dizziness.[4]

Adrogolide was under development by Abbott Laboratories and DrugAbuse Sciences.[1][2][3] It reached phase 2 clinical trials for Parkinson's disease prior to the discontinuation of its development in 2001.[1][2][3] The drug is said to have been the first extensively characterized dopamine D1 receptor full agonist.[4]

See also

References